These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. Butt JH; Yafasova A; Elming MB; Dixen U; Nielsen JC; Haarbo J; Videbæk L; Korup E; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Thune JJ; Køber L Circ Heart Fail; 2022 Sep; 15(9):e009669. PubMed ID: 35942877 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. Biton Y; Rosero S; Moss A; Zareba W; Kutyifa V; Baman J; Barsheshet A; McNitt S; Polonsky B; Goldenberg I Am J Cardiol; 2018 Mar; 121(5):615-620. PubMed ID: 29307459 [TBL] [Abstract][Full Text] [Related]
6. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266 [TBL] [Abstract][Full Text] [Related]
9. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction. van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031 [TBL] [Abstract][Full Text] [Related]
10. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020 [TBL] [Abstract][Full Text] [Related]
12. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811 [TBL] [Abstract][Full Text] [Related]
13. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. Providência R; Boveda S; Defaye P; Segal O; Algalarrondo V; Sadoul N; Lambiase P; Piot O; Klug D; Perier MC; Bouzeman A; Barra S; Bories MC; Gras D; Fauchier L; Bordachar P; Babuty D; Deharo JC; Leclercq C; Marijon E; Am J Cardiol; 2016 Oct; 118(8):1225-1232. PubMed ID: 27561197 [TBL] [Abstract][Full Text] [Related]